Page last updated: 2024-09-03

ak 2123 and Hypoxia

ak 2123 has been researched along with Hypoxia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aibe, N; Kagiya, T; Nakamura, S; Nishimura, T; Okabe, H; Yamazaki, H; Yoshida, K1
Banerjee, S; Chakraborty, S; Das, T; Kagiya, VT; Mukherjee, A; Nair, CK; Samuel, G; Sarma, HD; Venkatesh, M1

Other Studies

2 other study(ies) available for ak 2123 and Hypoxia

ArticleYear
Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (sanazole) for glioblastoma multiforme using simultaneous integrated boost technique.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; Hypoxia; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Triazoles

2013
Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia.
    Bioorganic & medicinal chemistry, 2004, Dec-01, Volume: 12, Issue:23

    Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Fibrosarcoma; Hypoxia; Lutetium; Mice; Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Triazoles

2004
chemdatabank.com